On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

Researchers Report First Successful Gene Therapy for Hemophilia A

In an ongoing phase I/II study of patients with hemophilia A, those who received a single infusion of BMN 270 (an adeno-associated virus serotype...

ZUMA-1 at One Year: Durable Responses to Axicabtagene Ciloleucel in Patients With Aggressive NHL

In October 2017, axicabtagene ciloleucel became the second chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration, and the...

“Intra-Bone” Gene Therapy Reduced Transfusion Need in Patients With Beta-Thalassemia

Gene therapy could represent an alternative to hematopoietic stem cell transplantation (HCT) – the only curative therapy for beta-thalassemia – and may offer several...

Palliative Care Use Infrequent in Patients with Hematologic Malignancies

Use of palliative care services among patients with hematologic malignancies is “sporadic at best,” and there was no clear subgroup receiving uniform care, according...

A New BTK Inhibitor on the Block: Zanubrutinib Demonstrates High Activity in Aggressive Non-Hodgkin...

Zanubrutinib (BGB-3111) is a potent, highly specific, and irreversible Bruton tyrosine kinase (BTK) inhibitor that is effective in treating aggressive B-cell malignancies, according to...

Phase I Trial Shows “Exciting” Results With Avapritinib in Advanced Systemic Mastocytosis

The oral KIT D816V inhibitor avapritinib (formerly known as BLU-285) could provide an alternative treatment option for patients with advanced systemic mastocytosis (SM), including...

Transfusion Dependence Delays Hospice Enrollment in Patients With Leukemia

Because many hospice organizations disallow life-extending transfusion support, transfusion dependence (TD) can pose a substantial barrier to enrolling patients with leukemia in palliative or...

Interim Results from the First-in-Human Trial of Antibody Drug Conjugate ADCT-402 in B-Cell Malignancies

In a first-in-human trial of loncastuximab tesirine, the CD19-targeting antibody drug conjugate (ADC) appeared to have manageable toxicity and encouraging efficacy as a single...

Preliminary Results Suggest Less-Frequent Emicizumab Dosing Feasible in Patients With Hemophilia A

In November 2017, the U.S. Food and Drug Administration (FDA) approved once-weekly dosing of the recombinant bispecific monoclonal antibody emicizumab for patients with hemophilia...

Lowering Emergency Department Reliance in Patients With Sickle Cell Disease

Thanks to new initiatives to improve care for patients with sickle cell disease (SCD) living in Wisconsin, fewer patients are visiting the emergency department...
Advertisement

Current Issue

December 2017, Volume 3, Issue 14

This issue features physicians' insights on gun control, the use of cannabis for symptom relief, and more.